Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone and Digoxin DDI Study
NCT03909529Phase 1Completed
- Sponsor
- CMP Development LLC
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spironolactone in heart failure (HF), hypertension (HTN), edema and 1 more (2 arms), sponsored by CMP Development LLC. Primary endpoints: Digoxin Plasma Maximum Concentration at 4 days and Digoxin Plasma Area Under the Curve at 4 days. Started Mar 2019; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure (HF)hypertension (HTN)edemaprimary hyperaldosteronism (PA)
Beyond the preview
Go deeper on NCT03909529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909529.